AFT to announce half year interim results Nov 20

24 October 2025


AFT Pharmaceuticals to announce half year interim results on Thursday November 20
2025


AFT Pharmaceuticals (NZX: AFT, ASX: AFP) announced today that it intends to release
on Thursday November 20 2025 its half year interim results for the period ended
September 30 2025. The release will be issued at around 09:00.

This will be followed by a presentation by management at 10:30 by teleconference.
The presentation material which will be referred to by management will be issued at
around 09:00 and will also be available on the company’s website aftpharm.com.

To attend the conference call, you will need to use the pre-registration link below.
Once you have completed this you will be provided with dial in details and a unique
pin code.

Registration Link: AFT conference call November 20 2025

For and on behalf of AFT Pharmaceuticals Limited, Malcolm Tubby, CFO.

For more information:


Investors Media
Malcolm Tubby Richard Inder
CFO, AFT Pharmaceuticals Ltd The Project
Phone: +64 9 488 0232 Phone: 021 645 643
Email: malcolm@aftpharm.com Email: richard@theproject.co.nz



About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical company that develops, markets and
distributes a broad portfolio of pharmaceutical products across a wide range of
therapeutic categories which are distributed across all major pharmaceutical
distribution channels: over-the-counter (OTC), prescription and hospital. Our product
portfolio comprises both proprietary and in-licensed products, and includes patented,
branded and generic drugs. Our business model is to develop and in-license products
for sale by our own dedicated sales teams in our home markets of Australia and New
Zealand and in certain Southeast Asian markets, and to out-license our products to
local licensees and distributors to the rest of the world. For more information:
aftpharm.com